Source comparison
BPC-157 Research Alcohol Considerations: Model Validity Comparison
Acute gastric ulcer Single ethanol dose (absolute ethanol, 1 mL) Administer BPC-157 30 min pre-exposure or 24 hrs post-exposure Pre-treatment: 60% lesion reduction; post-treatment: 45% lesion reduction High validity. Temporal separation isolates healing phase
This comparison does not assign a generated winner or score.
- Acute gastric ulcer
- Single ethanol dose (absolute ethanol, 1 mL)
- Administer BPC-157 30 min pre-exposure or 24 hrs post-exposure
- Pre-treatment: 60% lesion reduction; post-treatment: 45% lesion reduction
- High validity. Temporal separation isolates healing phase
- Chronic liver injury
- Daily ethanol gavage (5 g/kg) for 8 weeks
- Daily BPC-157 (10 mcg/kg SC) concurrent with ethanol
- 30–40% reduction in steatosis vs ethanol-only group
- Moderate validity. Interaction term quantified but mechanism overlap persists
- Tendon healing + alcohol use
- Chronic ethanol in drinking water (10% v/v)
- BPC-157 (10 mcg/kg IP) daily during 14-day repair window
- Delayed healing vs non-alcohol BPC-157 group (18 days vs 14 days to full strength recovery)
- High validity if control arms separate alcohol and BPC-157 independent effects
- Wound closure in diabetic + alcohol model
- Intermittent binge ethanol (3 doses/week)
- BPC-157 (500 mcg/kg SC) on non-ethanol days
- Wound closure rate intermediate between BPC-157-only and ethanol-only groups
- High validity. Staggered dosing prevents direct molecular interference
- This comparison demonstrates that protocol validity hinges on whether the research question is 'Does BPC-157 work in the presence of alcohol?' (requiring concurrent exposure) or 'Does BPC-157 repair alcohol-induced damage?' (requiring temporal separation). Both are legitimate questions, but they demand different designs.